Bio-Path issues Series S preferred to CEO entity, giving 51% voting control; cancels reverse split, plans trial restarts

BIO-PATH HOLDINGS, INC.

Issued 51 Series S preferred shares (1% vote each) and 2M warrants to CEO-controlled SGA, granting 51% voting control.
$10K accrued payables used as consideration for the preferred and warrants; no new capital raised.
Filing to domesticate to Wyoming from Delaware; expected approval March 2026.
In talks with creditors to restructure; plans to restart Phase 1/2 trials for AML, solid tumors, and obesity.
Canceled previously approved 1-30 reverse split; created Strategic Advisory Board and reserved 1.5M incentive stock options.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.